The two startups will utilise the capital for business growth including strategic expansion, product development, R&D and technology investments
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
The bank will provide a complete range of financing options including hospitals, labs, diagnostic centres and equipment manufacturers
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
It is the first-ever fully remote end-to-end Remote Patient Monitoring (RPM) service to include cardiac arrhythmia analysis in a single, intuitive platform
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Subscribe To Our Newsletter & Stay Updated
